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OBJECTIVES This study was designed to test the hypothesis that eptifibatide and reduced-dose tissue
plasminogen activator (t-PA) will enhance infarct artery patency at 60 min in patients with
acute myocardial infarction (AMI).
BACKGROUND Combination fibrin and platelet lysis improves epicardial and myocardial reperfusion in AMI.
METHODS Patients were enrolled in a dose finding (Phase A, n  344) followed by a dose confirmation
(Phase B, n  305) protocol. All patients received aspirin and weight-adjusted heparin and
underwent angiography at 60 and 90 min. In Phase A, eptifibatide in a single or double bolus
(30 min apart) of 180, 180/90 or 180/180 g/kg followed by an infusion of 1.33 or 2.0 g/kg
per min was sequentially added to 25 or 50 mg of t-PA. In Phase B, patients were randomized
to: 1) double-bolus eptifibatide 180/90 (30 min apart) and 1.33 g/kg per min infusion with
50 mg t-PA (Group I); 2) 180/90 (10 min apart) and 2.0 g/kg per min with 50 mg t-PA
(Group II); or 3) full-dose, weight-adjusted t-PA (Group III).
RESULTS In Phase A, the best rate of Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 was
achieved using 180/90/1.33 g/kg per min eptifibatide with 50 mg t-PA: 65% and 78% at 60
and 90 min, respectively. In Phase B, the incidence of TIMI flow grade 3 at 60 min was 42%,
56% and 40%, for Groups I through III, respectively (p 0.04, Group II vs. Group III). The
median corrected TIMI frame count was 38, 33 and 50, respectively (p  0.02). TIMI major
bleeding was reported in 8%, 11% and 6%, respectively; intracranial hemorrhage occurred in
1%, 3% and 2% of patients (p  0.5 for both). The incidences of death (4%, 5% and 7%),
reinfarction or revascularization at 30 days were similar among the three treatment groups.
CONCLUSIONS In comparison with standard t-PA regimen, double-bolus eptifibatide (10 min apart) with a
48-h infusion and half-dose t-PA (Group II) is associated with improved quality and speed
of reperfusion. The safety profile of this therapy is similar to that of other combination
regimens. (J Am Coll Cardiol 2002;39:377–86) © 2002 by the American College of
Cardiology
Rapid and complete restoration of blood flow achieved with
fibrinolytic therapy improves myocardial function and sur-
vival after acute myocardial infarction (AMI) (1). Neverthe-
less, current regimens of full-dose plasminogen activators
achieve Thrombolysis In Myocardial Infarction (TIMI)
flow grade 3 in 50% to 60% of patients by 90 min, and
approximately 20% of patients have a combination of
reocclusion or microvascular obstruction (2). In addition,
fibrinolytic agents are associated with a significant risk of
intracranial hemorrhage (ICH), particularly in older pa-
tients (3).
Given the key role platelets play in coronary thrombosis,
two recent studies (4,5) using abciximab and reduced-dose
tissue plasminogen activator (t-PA) or recombinant plas-
minogen activator have shown promising results. Eptifi-
batide, a peptide glycoprotein (GP) IIb/IIIa inhibitor with
rapid onset of action and reversibility, was previously eval-
uated in conjunction with full-dose t-PA (6) and streptoki-
nase (7). In the former study, a reduced dose of eptifibatide
combined with full-dose t-PA produced a substantially
higher rate of TIMI flow grade 3 at 90 min than t-PA alone
(66% vs. 39%, p  0.05). The latter study, using single-
bolus eptifibatide, demonstrated a significant increase in
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combined TIMI flow grade 2  3 at 60 min and a trend for
improved TIMI flow grade 3 (44% for combination therapy
vs. 31% for placebo). On the basis of accumulated pharma-
cokinetic data and modeling, double-bolus regimens were
designed to achieve and maintain a receptor occupancy
80% during the critical first 90 min after reperfusion
therapy (8). Thus, we performed a dose finding and confir-
mation study to test the angiographic efficacy of various
doses of bolus and infusion of eptifibatide and reduced-dose
t-PA in AMI.
METHODS
This was an angiographic, Phase II open-label trial with a
sequential design during the dose finding phase and formal
randomization during the confirmation phase. Between
February 17, 1998, and June 13, 2000, 649 patients with
AMI were enrolled at 55 centers in North America, Europe
and South Africa. Patients over the age of 18 were eligible
for enrollment if they presented with ischemic discomfort
for 20 min within 6 h of onset and ST-segment elevation
and were candidates for fibrinolytic therapy. Important
exclusion criteria included the usual contraindications to
fibrinolysis, previous surgical revascularization, serum creat-
inine 2.0 mg/dl, cardiogenic shock requiring intra-aortic
balloon counterpulsation, use of another GP IIb/IIIa recep-
tor antagonist within seven days, or known intolerance to
aspirin, heparin, eptifibatide or t-PA. After screening and
informed consent, patients received at least 160 mg aspirin
and heparin 4,000 U (60 U/kg for weight 70 kg) bolus
followed by an 800 U/h (12 U/h for weight 70 kg)
infusion, to maintain an activated prothrombin time of 50 to
70 s for up to 24 h. The protocol was reviewed and approved
at each institution by the appropriate ethics/investigation
review board.
Study Protocol
Dose finding phase (Phase A). Patients were enrolled
sequentially into eight different combination therapy regi-
mens, as shown in Table 1. Eptifibatide was administered
immediately after (within 30 min) t-PA, except in Groups
7 and 8 in which eptifibatide was given before t-PA (within
15 min). When double-bolus eptifibatide was used, it was
given 30 min apart. The eptifibatide infusion was continued
for 72 h. Tissue plasminogen activator was given as a 25 mg
bolus (Group 1 and 2) or 15 mg bolus and 60-min infusion
of 35 mg in Groups 3 to 8. Transition from dose regimen
group to group was based on a prespecified review by the
steering and safety committees of the safety and efficacy data
of at least 30 patients enrolled in a particular group.
Basis for double bolus regimens of eptifibatide. In addi-
tion to the approved single-bolus regimen of 180 g/kg
bolus and 2.0 g/kg per min infusion, eptifibatide was
administered in a double-bolus form of 180/90 g/kg and
180/180 g/kg. The dosing regimens used in clinical trials
of GPIIb-IIIa inhibitors have targeted a level of platelet
aggregation inhibition of at least 80% of baseline. An
eptifibatide plasma concentration of 1,600 ng/ml results in
the desired level of receptor occupancy and inhibition of
platelet aggregation. The single-bolus regimen of
180 g/kg achieves the minimum 1,600 ng/ml plasma
concentration. However, it is frequently accompanied by a
transient decrease in drug concentration below 1,600 ng/ml
at 30 to 60 min following the initial bolus (9–11).
Dose confirmation phase (Phase B). The best regimen
from the dose finding phase was selected for Phase B
(180/90 g/kg, 30 min apart plus a 1.33 g/kg per min
infusion, Group I). An additional eptifibatide dosing strat-
egy (180/90 g/kg, 10 min apart plus a 2.0 g/kg per min
infusion, Group II) was selected to ascertain whether the
interval between boluses has an effect on angiographic
patency (Table 1). This phase was open-label and was
initiated with a standard lytic arm (front-loaded, weight-
adjusted 90-min infusion of 100 mg of t-PA) serving as
the control group (Group III). In Group II, the infusion of
eptifibatide could be reduced to 1.33 g/kg per min if minor
bleeding occurred, according to investigator judgment. The
eptifibatide infusion was continued for a maximum of 48 h
(18 to 24 h if revascularization was performed).
Angiography. Angiography was performed at 60 and 90
min following administration of the t-PA bolus, unless the
investigator considered the need for immediate angioplasty
to be critical. An independent angiographic laboratory
adjudicated all films with respect to TIMI flow (12) and
corrected TIMI frame count (cTFC) (13). A value of 100
was assigned to patients with TIMI flow grade 0 to 1. The
reviewers were blind to patient assignment.
Primary and secondary end points. The primary efficacy
end point was the incidence of TIMI flow grade 3 at 60 
15 min after the administration of t-PA bolus (60 min
window). The key secondary end point consisted of the
incidence of TIMI flow grade 3 at 90  15 min (90 min
window). The primary safety end point was the incidence of
TIMI major bleeding during the initial hospitalization (4).
Patients were monitored for 30 days after enrollment for
the occurrence of death (cardiac or noncardiac), reinfarc-
tion, stroke (hemorrhagic or nonhemorrhagic), percutane-
ous or surgical revascularization, development of heart
Abbreviations and Acronyms
AMI  acute myocardial infarction
aPTT  activated prothrombin time
cTFC  corrected TIMI frame count
ECG  electrocardiogram
GP  glycoprotein
GUSTO  Global Utilization To Open occluded
coronary arteries
ICH  intracranial hemorrhage
LAD  left anterior descending artery
TIMI  Thrombolysis In Myocardial Infarction
t-PA  tissue plasminogen activator
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Table 1. Baseline Characteristics (Includes Patients Who Received Study Drug)
Group 1 2 3 4 5 6 7 8 I II III
Sequence t-PA Followed by Eptifibatide Eptifibatide Followed by t-PA
t-PA Followed by
Eptifibatide
t-PA 25 mg IV Bolus
15 mg IV Bolus 
35 mg IV Infusion Over 60 min
15 mg IV Bolus 
35 mg IV Infusion
Over 60 min
15 mg IV Bolus 
0.75 mg/kg Over
30 min  0.5 mg/kg
Over 60 min
Eptifibatide
Bolus #1 g/kg 180 180 180 180 180 180 180 180 180 180
Bolus #2 g/kg 90 90 180 180 90 90 90
Infusion g/kg per min 1.33 1.33 1.33 1.33 1.33 2.0 2.0 2.0 1.33 2.0
No. of patients 35 37 31 52 54 48 33 48 99 100 100
Age (yr) 63 (54,69) 62 (56,69) 61 (52,73) 60 (50,70) 60 (51,69) 60 (52,70) 59 (51,68) 59 (53,67) 60 (50,68) 59 (49,71) 59 (50,68)
Gender—male 23 (65) 29 (70) 26 (83) 34 (65) 39 (72) 36 (75) 26 (81) 42 (87) 73 (74) 78 (78) 78 (78)
HTN 17 (48) 16 (43) 13 (41) 21 (40) 17 (31) 20 (41) 14 (43) 20 (41) 46 (47) 36 (36) 41 (41)
Diabetes 9 (25) 8 (21) 5 (16) 9 (17) 9 (16) 11 (22) 6 (18) 4 (8) 16 (16) 21 (21) 13 (13)
Prior MI 4 (11) 4 (10) 4 (12) 7 (13) 7 (13) 3 (6) 4 (12) 4 (8) 16 (16) 18 (18) 16 (16)
Pain to Rx, h 3.1 3.3 2.7 2.8 2.9 3.1 3.2 3.3 2.9 3.0 3.0
Lytic to eptifibatide, min 16 (6,24) 11 (3,17) 11 (3,16) 9 (3,15) 10 (3,15) 5 (2,7) 6 (10,2) 8 (10,5) 3 (1,4) 3 (0,4)
Lytic to angio, min 60 60 60 60 59 60 59 58 60 57 58
MI Location
Anterior 11 (31) 12 (32) 5 (16) 15 (29) 24 (44) 22 (46) 12 (38) 23 (48) 37 (37) 36 (36) 33 (33)
Inferior 24 (69) 25 (68) 25 (81) 34 (65) 25 (46) 21 (44) 20 (63) 23 (48) 58 (59) 56 (56) 56 (56)
Other 7 (21) 11 (30) 10 (33) 19 (37) 16 (30) 14 (29) 8 (25) 6 (12) 30 (30) 36 (36) 26 (26)
Data presented as number (%) or medians (with 25th to 75th percentile), as appropriate.
HTN  hypertension; IV  intravenous; MI  myocardial infarction; t-PA  tissue plasminogen activator.
379
JACC
Vol.39,No.3,2002
Brener
et
al.
February
6,2002:377–86
Eptifibatide
and
t-PA
in
Acute
M
yocardialInfarction
failure or pulmonary edema, recurrent ischemia (5 min) or
cardiogenic shock.
Reinfarction in the first 24 h was diagnosed if ST
elevation reoccurred or there was re-elevation of CK-MB
(33% for a previous decrease from peak of 25% or 100%
for a preceding decrease of 50%). Reinfarction after 24 h
was diagnosed based on CK-MB re-elevation to above 3
times normal (2 times normal after day 7) or new significant
Q waves. Stroke was diagnosed on the basis of an imaging
study and an expert neurologist opinion. Percutaneous or
surgical revascularization was considered an end point if
performed for TIMI flow grade 3 flow. All patients had
an electrocardiogram (ECG) performed at baseline and 3 h
after administration of the t-PA bolus. An independent
ECG laboratory reviewed all tracings and determined the
degree of ST elevation resolution, according to Schroeder’s
criteria (14).
Statistics
Phase A. A minimum of 30 patients per group allowed for
at least 96% probability (one-sided) of detecting a TIMI
flow grade 3 of at least 60% based on a historical control rate
of 39% for full-dose t-PA at 60 min and at least 70% with
a historical control of 54% at 90 min. Enrolling 45 patients
in each group ensured at least a probability of 70% of
detecting a rate of major bleeding of at least 7% based on a
historical control rate of 5% (6).
Phase B. On the basis of these assumptions, enrolling 100
evaluable patients in each group afforded a 80% power
(two-sided, 0.05 alpha) to detect an absolute 20% difference
in the 60-min rate of TIMI flow grade 3 between each
experimental group and the control patients.
Data are presented, when appropriate, as number and/or
percentage of patients. Continuous data are presented as
means with standard deviation or medians with 25th to 75th
percentile ranges. Student t and Wilcoxon rank-sum tests
were performed, as indicated, without correction for
multiple-group comparison.
RESULTS
The baseline characteristics of the patients are shown in
Table 1. One-fourth of the patients were women and nearly
one-fifth had treated diabetes mellitus. The majority of
patients were current or recent ex-smokers, and a third of
the patients suffered an anterior infarction.
Angiographic outcome. The adjudicated incidence of
TIMI flow grade 3 in each stage and group at 60 and 90 min
is shown in Table 2. Of the 649 patients randomized, 641
(98.6%) received the assigned study drug regimen and an
angiogram and were thus considered the evaluable cohort
for the primary end point. In Phase A, patients receiving
half-dose t-PA over 1 h and double-bolus eptifibatide of
180 and 90 g/kg, followed by a 1.33 g/kg per min
infusion had the highest rate of TIMI flow grade 3 (Group
4) of 65% (95% confidence interval 52% to 78%) at 60 min
and 78% (65% to 91%) at 90 min. The cTFC analysis
confirmed this observation; median frame counts decreased
to 26 for this dose group and the cumulative frame count
demonstrated a left shift with the double-bolus regimen,
indicating more rapid blood flow. No incremental benefit
was seen as the dose of the second bolus was increased from
90 to 180 g/kg. Reperfusion regimens consisting of
quarter-dose t-PA were noted to be less effective.
Phase A provided a unique opportunity to evaluate the
effects of sequence of administration of eptifibatide and
t-PA on infarct artery patency. There was a statistically
significant increase in TIMI flow grade 3 at 60 and 90 min
in the groups that received t-PA followed by eptifibatide as
compared with the opposite sequence (Groups 3 and 4 vs.
Groups 7 and 8, p  0.046), confirmed by a significantly
lower cTFC (p  0.04, Fig. 1).
In Phase B, using the predefined window of 60 15 min,
patients assigned to Group II had a significantly higher
incidence of TIMI flow grade 3 compared with Group III
(56% [45% to 67%] vs. 40% [29% to 51%], respectively, p
0.04). However, this benefit was not apparent when the
interval between boluses was increased from 10 to 30 min
and the infusion was lowered (Group I vs. Group III). At
90 min, combination therapy (Group II) demonstrated a
trend toward a persistent advantage over the control patients
(Group III) (62% [51% to 73%] vs. 54% [42% to 66%], p 
0.11, respectively). The incidence of TIMI flow grade 3 at
60 and 90 min in the full-dose t-PA control group is
consistent with previous studies.
The incidence of TIMI flow grade 3 did not change
significantly if angiograms obtained outside of the prespeci-
fied time window were considered, using the best available
data. The rates of TIMI flow grade 3 in Groups I, II and III
at 60 and 90 min were 42%, 54% and 40% (p  0.04 for
Group II vs. Group III) and 46%, 59% and 47% (p  0.08
for Group II vs. Group III), respectively.
The cTFCs in the infarct-related artery in the three
groups of Phase B are shown in Table 2 and Figure 2.
Patients in Group II had a significantly lower median cTFC
than those in Group III (33 vs. 50, p  0.02, respectively)
at 60 min. There was an upward and leftward shift indicat-
ing faster flow in Group II compared with Group III (p 
0.02). No significant difference existed between Groups I
and III.
ST- segment resolution. The degree of complete (70%)
ST-segment elevation 3 h after the t-PA bolus is shown in
Table 3. In Phase A, the highest rate of resolution was
observed again in Group 4, corresponding to the highest
rate of TIMI flow grade 3. There were no significant
differences among the three groups in Phase B. There was
substantially more frequent complete resolution of ST-
segment elevation in patients with inferior MI (78%, 84%
and 80%) than in those with anterior MI (44%, 44% and
42%), for Groups I through III, respectively.
Clinical outcome. The incidence of death, reinfarction or
need for revascularization is listed in Table 3. There were no
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Table 2. Angiographic Results (Includes Patients Who Received Study Drug)
Group 1 2 3 4 5 6 7 8 I II III
Sequence t-PA Followed by Eptifibatide
Eptifibatide
Followed by t-PA
t-PA Followed
by Eptifibatide
t-PA 25 mg IV Bolus
15 mg IV Bolus 
35 mg IV Infusion Over 60 min
15 mg IV Bolus 
35 mg IV Infusion
Over 60 min
15 mg IV Bolus 
0.75 mg/kg Over
30 min  0.5 mg/kg
Over 60 min
Eptifibatide
Bolus #1 g/kg 180 180 180 180 180 180 180 180 180 180
Bolus #2 g/kg 90 90 180 180 90 90 90
Infusion g/kg/min 1.33 1.33 1.33 1.33 1.33 2.0 2.0 2.0 1.33 2.0
No. of Patients 35 37 31 52 54 48 33 48 99 100 100
60 min window 25 31 27 48 44 38 30 40 84 75 81
TIMI 3 12 (48) 14 (45) 16 (59) 31 (65) 27 (61) 17 (45) 14 (47) 20 (50) 35 (42) 42 (56) 32 (40)
TIMI 2/3 21 (84) 24 (77) 23 (85) 45 (94) 37 (84) 34 (89) 25 (83) 36 (90) 63 (75) 60 (80) 55 (68)
cTFC 33 (23,64) 49 (28,100) 31 (24,37) 26 (20,38) 35 (23,57) 36 (22,65) 41 (28,100) 37 (24,48) 38 (24,100) 33 (18,91) 50 (29,100)
60 min end point* 33 37 29 51 53 46 33 48 96 96 96
TIMI 3 17 (52) 17 (46) 17 (59) 33 (65) 33 (62) 18 (39) 16 (48) 22 (46) 40 (42) 52 (54) 38 (40)
TIMI 2/3 28 (85) 29 (78) 24 (83) 48 (94) 46 (87) 40 (87) 28 (85) 39 (81) 73 (76) 73 (76) 66 (69)
c-TFC 32 (22,64) 37 (25,100) 31 (24,57) 27 (20,39) 35 (22,54) 37 (25,66) 39 (26,71) 41 (24,60) 38 (23,100) 34 (19/100) 46 (26,100)
90 min window 28 32 26 37 39 40 20 29 72 79 69
TIMI 3 14 (50) 12 (38) 15 (58) 29 (78) 29 (74) 21 (53) 15 (75) 17 (59) 38 (53) 49 (62) 37 (54)
TIMI 2/3 23 (82) 28 (88) 22 (85) 35 (95) 37 (95) 35 (88) 20 (100) 27 (93) 62 (86) 65 (82) 54 (78)
cTFC 28 (24,62) 36 (25,61) 34 (21,60) 23 (14,38) 31 (23,38) 35 (22,53) 28 (19,37) 32 (24,44) 32 (22,55) 31 (14,92) 36 (22,100)
90 min end point 33 37 29 51 53 46 33 48 96 96 96
TIMI 3 18 (55) 14 (38) 18 (62) 37 (73) 36 (68) 24 (52) 18 (55) 25 (52) 44 (46) 57 (59) 45 (47)
TIMI 2/3 28 (85) 30 (81) 25 (86) 48 (94) 46 (87) 40 (87) 29 (88) 40 (93) 65 (68) 74 (77) 68 (71)
cTFC 28 (24,61) 37 (25,100) 32 (20,45) 25 (17,39) 31 (23,49) 34 (22,59) 36 (22,52) 32 (24,44) 36 (23,100) 31 (19,98) 41 (24,100)
*End point 60 Missing data estimated by selecting first available data as follows: TIMI-initial followed by TIMI 90 followed by TIMI-final. End point 90 Missing data estimated by selecting first available data as follows: TIMI-final
followed by TIMI 60 followed by TIMI-initial. Data presented as number (%) or medians with 25th to 75th percentile, as appropriate.
cTFC  corrected TIMI frame count; TIMI  Thrombolysis In Myocardial Infarction. Other abbreviations as in Table 1.
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significant differences among the three groups in Phase B.
Clinically indicated revascularization, defined as all coronary
artery bypass grafting (CABG) and percutaneous coronary
intervention for recurrent ischemia or TIMI flow grade 3,
was performed in 80 of 305 patients (26%) and was the
lowest in Group II (26%, 23% and 31% for Groups I
through III, respectively). There were 346 patients who
underwent percutaneous revascularization, 177 (52%) in
Phase A and 169 (55%) in Phase B. Of these, 24 (14%) in
Phase A and 33 (20%) in Phase B (13, 8 and 12 for Groups
I through III, respectively) had angioplasty before the
90-min angiogram.
Safety end points. Intracranial hemorrhage was reported
in 11 (1.7%, 95% confidence intervals 0.8% to 3.0%)
patients, whereas the overall rate of TIMI major hemor-
rhage using combination therapy was 10.5% (Table 3).
All-cause mortality was 4.8% (31/641 patients who received
study drug).
Phase A. Intracranial hemorrhage occurred in 5 (1.5%
[0.5% to 3.4%]) patients without apparent differences
among the regimens tested. The incidence of TIMI major
bleeding (excluding CABG) was 15% (n 48), the majority
of which was related to bleeding at the access site (12.8%,
n  44). The incidence of TIMI major bleeding (excluding
CABG) in the groups receiving single-bolus eptifibatide
(Groups 1, 3 and 7: 180 g/kg), double-bolus (Groups 2, 4
and 8: 180/90 g/kg) and higher double-bolus (Groups 5
and 6: 180/180 g/kg) was 9.3%, 17.1% and 19.4%,
respectively, p  0.14. Lower dose t-PA (Groups 1 and 2)
was not associated with less major bleeding. Moderate
thrombocytopenia (100,000 platelets/mm3) occurred in
13 patients (3.8%). Two patients (0.6%) experienced severe
thrombocytopenia (50,000 platelets/mm3). Transfusions
were administered in 16% (n  55), with the lowest rate in
Group 4 (13.2%).
Phase B. The incidence of TIMI major bleeding was 8%,
11% and 6%, in Groups I through III, respectively. A total
of six patients experienced ICH (one, three and two
patients, respectively, 2% [0.7%–4.4%], p  NS). Transfu-
sion of blood products occurred in 16%, 13% and 11%, but
only in seven patients excluding CABG (2.3%), and throm-
bocytopenia was not observed in any patient.
DISCUSSION
This study is the first systematic evaluation of eptifibatide
administered with reduced-dose t-PA for the treatment of
AMI and is one of four angiographic trials of a GPIIb IIIa
inhibitor combined with reduced-dose fibrin lysis com-
Figure 1. Corrected Thrombolysis In Myocardial Infarction (TIMI) frame
count for various sequences of administration of the components of the
combination regimen. The vertical lines at 27 and 40 frames indicate the
accepted upper limit of corrected TIMI frame count (cTFC) for TIMI
flow grade 3 and the breakpoint between TIMI flow grades 3 and 2,
respectively. t-PA  tissue plasminogen activator.
Figure 2. Corrected Thrombolysis In Myocardial Infarction (TIMI) frame count for the dose confirmation phase. The vertical lines at 27 and 40 frames
indicate the accepted upper limit of cTFC for TIMI flow grade 3 and the breakpoint between TIMI flow grades 3 and 2, respectively. t-PA  tissue
plasminogen activator.
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Table 3. Safety and Clinical Events Through 30 Days (All Randomized Patients)
Group 1 2 3 4 5 6 7 8 I II III
Sequence t-PA Followed by Eptifibatide
Eptifibatide
Followed by t-PA
t-PA Followed
by Eptifibatide
t-PA 25 mg IV Bolus
15 mg IV Bolus 
35 mg IV Infusion Over 60 min
15 mg IV Bolus 
35 mg IV Infusion
Over 60 min
15 mg IV Bolus
 0.75 mg/kg Over
30 min  0.5 mg/kg
Over 60 min
Eptifibatide
Bolus #1 g/kg 180 180 180 180 180 180 180 180 180 180
Bolus #2 g/kg 90 90 180 180 90 90 90
Infusion g/kg per min 1.33 1. 1.33 1.33 1.33 2.0 2.0 2.0 1.33 2.0
No. of patients 35 37 31 52 54 48 33 48 102 102 101
All-cause death 4 (12) 1 (3) 2 (6) 1 (2) 0 3 (6) 2 (6) 2 (4) 4 (4) 5 (5) 7 (7)
Cardiac death 2 1 2 1 0 1 1 1 3 3 4
Re-MI 0 0 1 (3) 4 (8) 1 (2) 2 (4) 3 (9) 1 (2) 8 (8) 2 (2) 3 (3)
ST analysis
No. of patients 29 33 27 48 42 35 25 37 86 83 85
70% resolution 22 (76) 25 (76) 18 (67) 38 (79) 27 (64) 19 (54) 17 (68) 26 (70) 56 (65) 57 (69) 56 (66)
PCI (clinically indicated) 9 (27) 12 (36) 8 (24) 13 (26) 12 (24) 12 (24) 10 (30) 11 (23) 26 (26) 23 (23) 31 (31)
Major bleeding
Non-CABG 1 (3) 4 (11) 2 (6) 4 (8) 6 (11) 8 (17) 4 (13) 8 (17) 8 (8) 11 (11) 6 (6)
Spontaneous 1 (3) 0 0 0 1 (2) 3 (6) 3 (9) 2 (4) 2 (2) 1 (1) 1 (1)
ICH 1 0 0 0 1 1 1 1 1 3 2
Thrombocytopenia (50,000/mm3) 0 0 0 1 0 0 0 1 0 0 0
Data presented as number (%) or medians (with 25th to 75th percentile), as appropriate.
CABG  coronary artery bypass grafting; ICH  intracerebral hemorrhage; IV  intravenous; MI  myocardial infarction; PCI  percutaneous coronary intervention; t-PA  tissue plasminogen activator.
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pleted to date (4,5,15). Two large trials assessing the effect
of combination therapy on mortality (16,17) have been
completed, creating a collective experience in excess of
20,000 patients.
Comparison with similar studies. This trial demonstrated
that eptifibatide-mediated inhibition of platelet aggregation
in conjunction with half-dose t-PA enhances the rate of
TIMI flow grade 3, and even more importantly, speeds the
process of reperfusion, such that most of the effect is already
observed by 60 min. Phase A showed that a double-bolus
strategy of eptifibatide coupled to reduced-dose (50 mg)
t-PA yielded TIMI flow grade 3 rates at 60 and 90 min that
exceed previously reported reperfusion rates with t-PA
alone. Moreover, the TIMI flow grade 3 observed in this
study compared favorably with other combination regimens
and with data from large studies of primary angioplasty (18).
In Phase B, the combination regimen demonstrated a 16%
absolute advantage over full-dose t-PA at 60 min. However,
this advantage was only seen when the double-bolus regi-
men was given at the shorter 10-min interval and in
conjunction with the higher infusion rate. This finding
highlights the fact that an aggressive strategy of platelet
GPIIb/IIIa receptor inhibition and fibrinolysis enhances the
speed and rate of reperfusion. This 16% advantage in TIMI
flow grade 3 is similar to the 18% difference observed at
60 min in the TIMI 14 trial (4), and superior to the 7%
difference noted in the Strategies for Patency Enhancement
in the Emergency Department (SPEED) study (5). The
reduction in the difference between the combination and
control patients at 90 min is likely due to the widespread use
of PCI (15%) before the 90-min angiographic end point.
Furthermore, when the continuous variable of cTFC is
analyzed (Fig. 3), there is remarkable consistency between
this study and the two previously reported studies of
abciximab (19). The rather large differences in arterial
patency for the 180/90/1.33 eptifibatide regimen between
the two phases of the study highlight the limitation of very
small groups of patients studied for an angiographic end
point, although the results in Phase B fall within the 95%
confidence interval for Phase A. Noteworthy is the fact that
Group 4 had a lower incidence of left anterior descending
coronary artery infarct (30%), which was an independent
predictor of failed lysis in TIMI 14.
Myocardial reperfusion, represented by complete resolu-
tion of ST-segment elevation, was frequent in this study. In
phase B, there were no significant differences among the
three groups, in whom two-thirds of the patients demon-
strated excellent reperfusion. However, the second ECG
was performed after PCI in more than half of the cases.
Therefore, direct comparison of our ECG data with other
combination therapy studies cannot be made (20).
Higher rates of bleeding complications were reported in
Phase A than in similar studies, particularly among recipi-
ents of the 180/180 g/kg double-bolus of eptifibatide. The
dose of t-PA did not appear to impact on hemorrhagic risk.
In Phase B, the incidence of major bleeding was similar to
that observed in the other trials and in line with AMI trials
with mandatory angiography and high rates of immediate
revascularization. As a comparison, the incidence of TIMI
major bleeding was 7% in the combination abciximab and
t-PA in TIMI 14 (4). In SPEED (5), severe hemorrhage
occurred in 9.8% of the 112 patients treated with the
combination regimen. When full-dose t-PA was used either
alone or in conjunction with escalating modest doses of
eptifibatide (36 to 180 g/kg bolus and 0.2 to 0.75 g/kg
per min infusion), the rate of severe hemorrhage was only
2% for the combination group and 5% for t-PA alone,
suggesting that more aggressive platelet inhibition plays an
important role in this complication (6). Nevertheless, ap-
proximately 75% of the bleeding episodes occurred at the
catheterization access site, suggesting that meticulous atten-
tion to sheath care and removal and judicious antithrombin
therapy may alleviate this problem. Overall, non-ICH
bleeding complications had little impact on the clinical
outcome. In general, the rate of major hemorrhage is
expected to be higher in angiographic studies because of the
mandatory instrumentation, and indeed there is an 8–10%
incidence of major hemorrhage in the primary angioplasty
studies, in which lytic therapy is not administered (21).
Typically, the definition of major bleeding in those studies
was also less stringent than the TIMI criteria.
Study limitations. A number of issues regarding combina-
tion therapy for AMI have not yet been addressed. First, it
is not clear whether differences in the fibrinolytic agents
influence outcome. Second, the incidence of major clinical
end points was low, and thus we cannot be certain that the
angiographic superiority demonstrated by the combination
regimens will translate into survival benefit or a reduction in
recurrent ischemic events. Particular attention should be
paid to the incidence of ICH, because an important goal of
the combination therapy is to minimize this dreaded com-
plication. The large Global Utilization of Strategies To
Open occluded coronary arteries (GUSTO) V-AMI study,
comparing standard fibrinolysis with the SPEED regimen
of combination therapy, did not show an increase in ICH in
the combination therapy arm, except for patients older than
75 years. Third, we did not adjust statistically for multiple
group comparisons, which could have exaggerated the actual
significance of differences between groups. Finally, approx-
imately 20% of the patients in the confirmation phase did
not undergo angiography per protocol. Nevertheless, using
the data closest to the prespecified window and including
95% of the patients did not alter the results substantially.
Conclusions. Double-bolus (within a 10-min interval) and
high-dose infusion of eptifibatide combined with half-dose
t-PA is superior to standard dose t-PA alone in achieving
reperfusion of the infarct-related artery 60 min after initia-
tion of therapy. The 16% absolute difference in TIMI flow
rate 3 is comparable to the results of similar studies and was
achieved without a significant increase in major bleeding
events, although a higher nominal rate of ICH was observed
in the patients with the highest rate of reperfusion. More
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than 75% of the episodes of major bleeding were associated
with the catheterization access site and did not affect clinical
outcome. The clinical utility of this strategy hinges on the
tradeoff between safety and efficacy and awaits confirmation
in larger clinical trials designed to detect differences in
mortality and other key outcomes of AMI.
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